AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06326411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-628
Description: NST-628 is a small molecule non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway.
Study NCT06286202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation: Adapted Neuropsychological and Education Approach to Remediation (NEAR)
Description: NEAR consists of computer-assisted cognitive exercises to restore cognitive functioning through rehearsal and strategy learning. Based on the results of the baseline assessments, the therapist will complete the Cognitive Remediation Treatment Plan, to outline targeted cognitive domains and functional goals. During the cognitive games sessions, the Multicontext Treatment Approach will be used, where error patterns are identified. The participants will work on metacognition and use of strategies to overcome challenges faced during the computer games sessions. Bridging groups may include activities for participants to utilize strategies learnt during the computer game sessions to everyday living. Participants will also learn about cognitive impairments and how lifestyle modifications, mood regulation etc can affect cognitive performance. In addition, they will learn about metamotivation and build awareness about their motivation levels through self- reflection and self-monitoring.
Study NCT06286202 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Psychiatric Rehabilitation at Anglican Care Centers
Description: Participants in the control arm will attend their usual psychiatric rehabilitation activities. These activities may include vocational training, community living skills training, psychoeducation, social skills training and peer support etc. These activities are also undertaken by participants in the experimental arm.
Study NCT04856358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3121
Description: GLPG3121 modified-release tablet
Study NCT04497922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-ink screen
Description: A virtual display screen developed by e-ink that displays patient status, basic demographics, care team information, pending tests and anticipated disposition
Study NCT04497922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual in the emergency department with communication of testing results, imaging and disposition by the primary clinical emergency department team.
Study NCT04980443 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CELTiC test
Description: The CELTiC test is a blood-based test consisting of four mRNA markers and the risk factor age.
Study NCT05216887 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aducanumab
Description: Administered as specified in the treatment arm.
Study NCT05216887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: Administered as specified in the treatment arm.
Study NCT04992182 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.3 mL IM saline solution
Study NCT04992182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated vaccine booster
Description: 0.5 mL IM
Study NCT04992182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA vaccine booster
Description: 0.3 mL IM
Study NCT04992182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viral vector vaccine booster
Description: 0.5 mL IM
Study NCT04856358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT06206564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate ointment
Description: Four 5-day cycles of artesunate ointment given at weeks 0, 2, 4, 6
Study NCT06206564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four 5-day cycles of placebo ointment given at weeks 0, 2, 4, 6
Study NCT01052727 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Cholecystectomy
Study NCT04953858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Social network strategy (SNS)
Description: SNS utilizes peers to reach and recruit their network members into HIV services, therefore having the advantage that recruiters with different behavioral risks and HIV statuses are likely to have access to a wide variety of HIV at risk populations
Study NCT05360004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Description: CHM is in the form of granules (9 g/sachet), which is comprised of 10 commonly used medicinal herbs: Codonopsis Radix, Astragali Radix, Lonicerae Japonicae Flos, Saposhnikovia Radix, Schizonepetae Herba, Mori Folium, Poria, Atractylodis Rhizoma, Atractylodis Macrocephala Rhizoma, Glycyrrhizae Radix et Rhizoma.
Study NCT05360004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese herbal medicine
Description: CHM is in the form of granules (9 g/sachet), which is comprised of 10 commonly used medicinal herbs: Codonopsis Radix, Astragali Radix, Lonicerae Japonicae Flos, Saposhnikovia Radix, Schizonepetae Herba, Mori Folium, Poria, Atractylodis Rhizoma, Atractylodis Macrocephala Rhizoma, Glycyrrhizae Radix et Rhizoma.
Study NCT05381610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peristeen
Description: The Peristeen system will be handled by Coloplast trained personnel. The investigator and a trained nurse will participate in all the investigation related procedures. The nurse is trained in the handling of the investi-gational product as well as this is described in detail in the Instruction for Use (IFU). Subjects (and their caregivers, if appropriate) will also be trained on the use of Peristeen prior to independent use at home.
Study NCT05514782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cleansing Lotion
Description: Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).
Study NCT05514782 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cleansing Lotion
Description: Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).
Study NCT05514782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Moisturizer
Description: Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen.
Study NCT05514782 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Facial Moisturizer
Description: Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen.
Study NCT05514782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen SPF 40+
Description: Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an Over the counter
Study NCT05514782 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunscreen SPF 40+
Description: Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an Over the counter
Study NCT06025773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Description: AD-2121 (Lansoprazole 15 mg), Oral, Capsule
Study NCT06025773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15mg/Calcium carbonate 600mg
Description: AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet
Study NCT04600193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet containing organic phosphate
Description: The patients will be receiving a 5 days diet containing organic phosphate
Study NCT04600193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet containing inorganic phosphate
Description: The patients will be receiving a 5 days diet containing inorganic phosphate
Study NCT04639245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT04639245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04639245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04639245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells
Description: Given IV
Study NCT04639245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD1 Inhibitor
Description: Given IV
Study NCT05530252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral biological antimicrobial gel
Description: The patients were divided into subgingival scaling, and Oral Biological Antimicrobial Gel was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
Study NCT05530252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline hydrochloride ointment
Description: The patients were divided into subgingival scaling, and minocycline hydrochloride ointment was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
Study NCT05530252 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SRP
Description: only scaling and root planning was performed on the patient
Study NCT06292286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carboplatin or cisplatin
Description: Carboplatin of cisplatin for 3-6 cycles
Study NCT06292286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar
Description: Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles
Study NCT06292286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab or biosimilar
Description: Optional
Study NCT06292286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery after chemotherapy
Study NCT06473857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental health literacy intervention
Description: Online interventions for adolescents and young adults on mental health literacy, 3 modalities : webconferences, build battle, serious games
Study NCT06473857 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non mental health intervention
Description: Online interventions for adolescents and young adults on other topics, 3 modalities : webconferences, build battle, serious games
Study NCT05511233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: feeding with breastmilk within 48 hours after surgery
Description: Electronic health records of babies who feed and not fed with breastmilk within 48 hours after surgery
Study NCT06598085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Description: Surgery with the Cornerstone Surgical Robot.
Study NCT04234477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-blocker strategy
Description: Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
Study NCT04234477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker strategy
Description: Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
Study NCT04234477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician preference strategy
Description: This strategy allows for usual care, with providers selecting their preferred rate-control agent. IV beta-blockers available through the inpatient pharmacy include metoprolol or esmolol, and IV calcium channel blockers include diltiazem and verapamil.
Study NCT06429917 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Subgingival instrumentation
Description: All the participants will undergo subgingival instrumentation with hand scalers, curettes and ultrasonic scaler. Parameters will be recorded at baseline and two, three and six months of time points after subgingival instrumentation.
Study NCT05306873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily~Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening~Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily
Study NCT05306873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Mycophenolate Mofetil
Description: Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily
Study NCT05306873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Description: Weeks 1-24: 23.7 mg Voclosporin (3 x 7.9 capsules) twice daily
Study NCT05306873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Voclosporin
Description: Weeks 1-24: 23.7 mg Placebo for Voclosporin (3 x 7.9 capsules) twice daily
Study NCT05306873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Stage 3 Dosing:~Participants who received placebo MMF in Stage 2:~* Week 1: Participants will receive 500mg MMF plus matching placebo for MMF (to appear like a 1000mg dose) twice daily~* Week 2: Participants will receive 500mg plus matching placebo for MMF (to appear like a 1000mg dose) and 1000mg in divided doses~* Weeks 3-24: 1000mg MMF twice daily~Participants who received MMF in Stage 2~• Week 1-24: 1000mg MMF twice daily
Study NCT05534165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecovirimat
Description: 600 mg po BID
Study NCT05534165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebo 600 mg po BID
Study NCT05030337 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Closed-loop automated oxygen control (Oxygenie, SLE 6000)
Description: The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
Study NCT06264843 — intervention group
Intervention type: DEVICE
Intervention: MiraQ with Transit-Time Flow Measurement (TTFM) and L15 High Frequency Ultrasound (HFUS) probes
Description: Identify and validate intraoperative TTFM and HFUS findings (e.g. threshold values of Mean Graft Flow (MGF), MGF capacity, flow curve pattern, morphological issues)
Study NCT05972317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP dietary regimen
Description: intervention will include a guidance by a clinical dietitian about low FODMAP diet~The FODMAP diet has three phases:~1. Elimination - Avoidance from high-FODMAP foods (2-6 weeks)~2. Reintroduction -Structured challenges of specific food groups each time (6-8 weeks).~3. Maintenance - personalized diet, according to the response in step 2.
Study NCT05967585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Behavioral: Quitting Program (TIQ)
Description: Implementation processes developed in Phase 1 to develop assessment of vaping behaviors and referral to an evidence-based program for vaping cessation (TIQ) will be tested in Phase 2.~TIQ program is a mHealth, text messaging based intervention. Users who enroll in this program will receive 1 to 2 messages per day with 3 messages sent on their quit date. Messages are tailored to users' age, enrollment date or quit date, and the vape product they use.~Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for up to 6 weeks preceding the date and up to 8 weeks after that include encouragement, support, skill- and efficacy- building exercises, coping strategies, etc. Keywords such as COPE, STRESS, SLIP, and MORE can be used to request on-demand support.
Study NCT06579261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Shamanism
Description: Each Shamanic intervention session, led by the shamanic practitioner, will include classical music as a control, followed by repetitive drumming and/or rattling music which the participant and shamanic practitioner will listen to for 15-30 mins. Following listening to drumming, the patient will then talk with the shamanic practitioner to debrief the experience of each session. Participants will also listen to classical music as a control stimulus.
Study NCT05732311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittend theta burst stimulation
Description: intermittend theta burst stimulation
Study NCT05732311 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittend theta burst stimulation
Description: intermittend theta burst stimulation
Study NCT06566989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]Opevesostat
Description: Oral solution
Study NCT06566989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Tablet
Study NCT06566989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: Tablet
Study NCT05349487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeakFree HME Hands Free Valve
Description: A voice prosthesis, SpeakFree HME Hands Free Valve, achieved with creation of a tracheoesophageal puncture will be placed over the stoma for 1 month.
Study NCT05349487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Occlusion
Description: Using participant's own fingers, they will be putting their fingers over the stoma.
Study NCT05349487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Depression HME
Description: A digital handheld press-down HME will be placed over stoma.
Study NCT05122806 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: RNAseq
Description: 1. Tissue : RNAseq will be performed on tumor biopsy (10 slides of 5 microns) to identify the ALK fusion partner and its variant and associated co-mutations.~2. ctDNA : NGS panel on DNA including a large panel of fusions and mutations will be performed on blood samples
Study NCT05132556 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acute Beetroot Juice
Description: Participants will ingest a beetroot juice supplement with and without inorganic nitrate to determine the effects of acute dietary nitrate ingestion on blood pressure and arterial stiffness
Study NCT05132556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Beetroot Juice
Description: Participants will ingest a beetroot juice supplement with and without inorganic nitrate to determine the effects of acute dietary nitrate ingestion on blood pressure and arterial stiffness
Study NCT05274997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: Linperlisib is a strong and selective small-molecule PI3K-δ (a protein involves in the survival of cells) inhibitor, which is able to interfere with the growth, migration and survival of T/NK lymphoma cells.
Study NCT05778877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-302
Description: SEL-302 Drug: MMA-101 (1.0E13 vg/kg)~Drug: SEL-110 (0.15 mg/kg or up to 0.3 mg/kg)~Other Names:~SEL-110.36, ImmTOR
Study NCT06235944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal block
Description: Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume 1ml/ kg max 20 ml via Ultrasound Guided caudal Block.
Study NCT06235944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacral erector spinae block
Description: Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume of 1 ml/ kg maximum 20ml divided in both sides via ultrasound guided sacral erector spinae plain block (ESPB).
Study NCT05391737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography after swimming (acute) and at rest (baseline)
Study NCT05391737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram (ECG)
Description: Electrocardiogram (ECG) after swimming (acute) and at rest (baseline)
Study NCT05391737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac biomarkers
Description: high sensitive (hs)-Troponin I and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) after swimming (acute) and at rest (baseline)
Study NCT05467059 — intervention group
Intervention type: OTHER
Intervention: Napping
Description: Patients are already equipped with electrodes when they pass a test battery before the nap to evaluate mechanisms potentially correlated with tinnitus modulation. Then they do a nap, the nap is stopped when several periods of sleep are seen on EEG (electroencephalogram). Then the test battery is done backwards to evaluate the same measures.